Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below and a pharmaceutical composition comprising the conjugate are provided. In the conjugate, P is a water soluble polymer; X is a linking group, wherein the linking group links P and A 1 ; each of A 1 , A 2 and A 3 is independently same or different amino acid residue or amino acid analogue residue; each of D 1 and D 2 is independently same or different drug molecule residue; a is 0 or 1; b is an integer of 2-12; c is an integer of 0-7; d is 0 or 1. The conjugate could improve drug load capacity, water solubility, stability and activity of the drug.
1. A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below:
wherein P is a water soluble polymer;
X is a linking group, wherein the linking group links P and A 1 ;
each of A 1 is independently same or different amino acid residue or amino acid analogue;
each of A 2 and A 3 is independently alanine or valine;
each of D 1 and D 2 is independently same or different drug molecule;
a is 0 or 1;
b is an integer of 2-12;
c is an integer of 0-7; and
d is 0 or 1.
2. The conjugate according to claim 1 , wherein P is selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, poly(glutamic acid), poly(aspartic acid), polyvinylpyrrolidone, polyvinyl alcohol, polypropylene morpholine, glucan, carboxymethylcellulose and analogue or copolymer thereof.
3. The conjugate according to claim 2 , wherein P is PEG and the molecular weight of the PEG is 300-60,000 Daltons.
4. The conjugate according to claim 3 , wherein the molecular weight of the PEG is 20,000-40,000 Daltons.
5. The conjugate according to claim 4 , wherein the PEG is linear, Y shape branched or multi-arm PEG.
6. The conjugate according to claim 2 , wherein the PEG has a structure shown in Formula (II) below:
R 1 —O CH 2 CH 2 O e Formula (II),
wherein R 1 is C 1-12 alkyl, C 1-12 heteroalkyl, hydrogen or arylalkyl; and e is an integer of 10-1,500.
7. The conjugate according to claim 1 , wherein P has a structure shown in Formula (III) below:
wherein each of R 2 and R 3 is independently C 1-12 alkyl, C 1-12 heteroalkyl, hydrogen, or arylalkyl;
each of R 4 R 5 is independently C 1-12 alkyl, or C 1-12 alkylcarbonyl; and
each of f and g is independently an integer of 10-1,500.
8. The conjugate according to claim 7 , wherein R 2 and R 3 are methyl, R 4 is ethyl, and R 5 is methylenecarbonyl.
9. The conjugate according to claim 1 , wherein P has a structure shown in Formula (IV) below:
R 6 O CH 2 CH 2 O h i Formula (IV),
wherein R 6 is pentaerythritol, methylglucoside, sucrose, diethylene glycol, propanediol, glycerol or polyglycerol whose hydrogen in hydroxyl group is removed; i is 3, 4, 6 or 8; and h is an integer of 10-1,500.
10. The conjugate according to claim 1 , wherein X is (CH 2 ) n , (CH 2 ) n CO, (CH 2 ) n OCO, (CH 2 ) n NHCO, —S—, —SO 2 —, or —SO 4 —; and n is an integer of 1-12.
11. The conjugate according to claim 10 , wherein X is CH 2 CO.
12. The conjugate according to claim 1 , wherein A 1 is an amino acid residue or an amino acid analogue with at least two carboxylic groups and one amino group.
13. The conjugate according to claim 12 , wherein A 1 has a structure shown in Formula (V) below:
wherein R 7 is C 1-20 alkyl or C 1-20 heteroalkyl.
14. The conjugate according to claim 12 , wherein A 1 has a structure shown in Formula (VI) below:
wherein each of R 8 and R 9 is independently hydrogen, C 1-12 alkyl, C 1-12 heteroalkyl, aryl, heteroaryl, aralkyl, or heteroarylalkyl, and R 8 and R 9 in each repeat unit are same or different; and j is an integer of 1-10.
15. The conjugate according to claim 12 , wherein A 1 is an aspartic acid residue or glutamic acid residue.
16. The conjugate according to claim 1 , wherein A 2 and A 3 are valine.
17. The conjugate according to claim 1 , wherein each of D 1 and D 2 is independently an anti-tumor drug.
18. The conjugate according to claim 17 , wherein the anti-tumor drug forms peptide or ester bond with A 2 or A 3 .
19. The conjugate according to claim 17 , wherein the anti-tumor drug is dasatinib, rapamycin, irinotecan, imatinib, erlotinib, gefitinib, lapatinib, sorafenib, sunitinib, paclitaxel, camptothecin, cinobufagin, glycyrrhetinic acid, or scopoletin.
20. The conjugate according to claim 19 , wherein the anti-tumor drug is dasatinib.
21. The conjugate according to claim 1 , wherein the conjugate has a structure shown in Formulas (IX), (X), or (XI) below:
wherein each of e, f and g is independently an integer of 10-1,500; and
wherein D 1 and D 2 are the same drug.
22. The conjugate according to claim 21 , wherein D 1 and D 2 are dasatinib.
23. A pharmaceutical composition comprising the conjugate according to claim 1 and a pharmaceutically acceptable carrier or excipient.
24. The pharmaceutical composition according to claim 23 , wherein the pharmaceutical composition is in the form of tablet, capsule, pill, granules, powder, suppository, injection, solution, suspension, ointment, patch, lotion, drop, liniment, or spray.